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Abstract
Background : This manuscript serves as an update to position papers published
in 2014 based on the available Belgian hepatitis C virus (HCV) epidemiological
data. Methods : Building on the current standard of care (2015 : 900 ≥ F3 patients
treated with 70-85% SVR), four new scenarios were developed to achieve the
goals of near viral elimination and prevention of HCV associated morbidity and
mortality by 2026 and 2031. Increases in treatment efficacy were assumed in
2016 (90% SVR) and 2017 (95% SVR). Results : Scenario 1 : Treating 6,670
patients annually by 2018 (≥ F0 beginning in 2017) and diagnosing 3,790 patients
annually by 2020, a 90% reduction in viremic cases and advanced outcomes was
observed by 2026. Scenario 2 : Treating 4,300 patients annually by 2018 (≥ F0
beginning in 2020) without increasing the number diagnosed, a 90% reduction in
viremic cases and 85%-95% reduction in advanced outcomes was observed by
2031. Scenario 3 : Treating 5,000 ≥ F2 patients annually by...
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Abstract
Background : This manuscript serves as an update to position 
papers published in 2014 based on the available Belgian hepatitis C 
virus (HCV) epidemiological data. 
Methods : Building on the current standard of care (2015 : 
900 ≥ F3 patients  treated with 70-85% SVR),  four new scenarios 
were developed to achieve the goals of near viral elimination and 
prevention of HCV associated morbidity and mortality by 2026 
and  2031.  Increases  in  treatment  efficacy were  assumed  in  2016 
(90% SVR) and 2017 (95% SVR). 
Results : Scenario 1 : Treating 6,670 patients annually by 2018 
(≥ F0 beginning in 2017) and diagnosing 3,790 patients annually by 
2020,  a  90%  reduction  in  viremic  cases  and  advanced  outcomes 
was observed by 2026. 
Scenario 2 : Treating 4,300 patients annually by 2018 (≥ F0 be-
ginning in 2020) without increasing the number diagnosed, a 90% 
reduction  in  viremic  cases  and  85%-95% reduction  in  advanced 
outcomes was observed by 2031. 
Scenario 3 : Treating 5,000 ≥ F2 patients annually by 2018, and 
diagnosing  3,620  patients  annually  by  2020,  a  90%  reduction  in 
 advanced  outcomes  and  50%  reduction  in  viremic  cases  was 
 observed by 2026. 
Scenario  4 :  Treating  3,100  ≥ F2  patients  annually  by  2018 
 without increasing the number diagnosed, a 90%-95% reduction in 
advanced  outcomes  and  55%  reduction  in  viremic  cases  was 
 observed by 2031. 
Conclusions :  Scenario  2  would  provide  the  most  favorable 
 balance  of  outcomes  (90%  reduction  in  viremic  prevalence  and 
 advanced outcomes) and realistic requirements for implementation 
(gradual  increase  in  treatment, delayed  incorporation of patients 
with no/mild fibrosis). (Acta gastro enterol. belg., 2015, 78, 228-232).
Key words : HCV mortality, hepatocarcinoma, interferon free treat-
ment costs, viral elimination.
Background
In 2014, the Belgian Working Group for HCV pub-
lished a series of position papers based on the available 
hepatitis C virus (HCV) epidemiological data in Belgium 
as well as the impact of modeled scenarios on the antici-
pated disease and cost burden associated with untreated 
HCV through 2030 (1-4). This exercise was part of a 
larger effort to quantify the burden of HCV world-
wide (5-10) and followed a standard methodology (10). 
Since completion of this analysis, however, the HCV 
landscape in Belgium has changed more rapidly than ex-
pected, and previously modeled scenarios have already 
become outdated. 
Beginning on January 1, 2015, all oral treatment with 
Sofosbuvir and Simeprevir became available in Belgium 
(much earlier than initially modeled). Access to this 
treatment is currently limited to patients with advanced 
fibrosis (≥ F3). Today, nearly all ≥ F3 patients with geno-
type 1 (G1) or G4 are being treated with this interferon 
free regimen (sofosbuvir-simeprevir +/- ribavirin). With-
in the next year, an additional antiviral, daclatasvir, is 
anticipated to become available in Belgium, extending 
interferon-free treatment options to G3 patients with 
 advanced fibrosis.
Given the expanding treatment landscape, an updated 
analysis was conducted to explore steps necessary to sub-
stantially reduce the burden of HCV, including scenarios 
to 1) achieve near-viral elimination (90% reduction of 
viremic cases) and 2) prevent HCV-associated morbidity 
and mortality (90% reduction of advanced outcomes, 
 including hepatocellular carcinoma [HCC] and liver re-
lated mortality). These outcomes have been assessed at 
two endpoints, 10 years (2026) and 15 years (2031), for a 
total of four scenarios. 
Methods 
A Microsoft Excel-based model was populated with 
Belgian data as previously described (2-4,10). 
Modeled scenarios and baseline treatment assumptions
Current Standard of Care (SOC) : Under the current 
SOC scenario, prior to 2015, 710 patients (11) were treat-
ed annually with Peg/IFN + RBV (sustained viral re-
sponse [SVR] 40%-65%, based on genotype) (12,13). 
Treatment was provided for adults (≥ 18 years of age) of 
all fibrosis stages (≥ F0 for G2 and ≥ F2 for G1, G3 and 
G4). Approximately 40% of patients were contra-
indicated for treatment or refused treatment altogether. 
Beginning in 2015, an estimated 900 patients were treat-
ed annually with new therapies (SVR G1, G2& G4-85% ; 
SVR G3-70%), with treatment restricted to ≥ F3 patients.
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Results
Current SOC
Under the current SOC described above, viremic 
 infections would decrease from 67,200 in 2015 to 53,000 
in 2026 and 46,300 in 2031 (Table 1). HCV-related 
 prevalent HCC and liver-related deaths, however, would 
increase from 290 and 415 in 2015 to 330 and 480, re-
spectively, in 2026. By 2031, HCC would decrease to 
315 and liver-related deaths would remain constant at 
480 (Table 1). The cumulative cost burden of untreated 
HCV would be € 1,136 M over 10 years (2016-2026), or 
€ 1,709 M over 15 years (2016-2031) (Table 2).
Scenario 1 : Near-viral elimination (90% reduction in 
viremic cases) in 10 years
In order to achieve near-viral elimination in 10 years, 
the number of patients treated with higher SVR therapies 
would need to be increased annually, from 900 in 2015 to 
6,670 in 2018, with a 10% increase in annual diagnosed 
patients (from 2,850 in 2015 to 3,790 in 2020). Addition-
ally, treatment would be available to ≥ F2 patients in 
2016 and all patients (≥ F0) beginning in 2017. This 
 scenario would result in a 90% reduction in total HCV 
infections, HCV-related HCC and liver-related deaths by 
2026 (Fig. 1). The cumulative cost savings, compared 
with the current SOC, would be € 530 M (45%), over 
10 years (Fig. 2a).
Modeled scenarios : Beginning in 2016, new scenari-
os included an increase in SVR to 90% for all genotypes. 
The percent of patients contraindicated for, or refusing, 
treatment was reduced to 10% to reflect the increased tol-
erability of treatment regimens. In 2017, a final increase 
in SVR to 95% was modeled in all patients.
Assuming increased treatment efficacy as described 
above, four scenarios were developed to explore two 
 primary outcomes with two primary endpoints :
Scenario 1 : Near-viral elimination (90% reduction in 
viremic cases) in 10 years
Scenario 2 : Near-viral elimination (90% reduction in 
viremic cases) in 15 years
Scenario 3 : Morbidity and mortality prevention (90% 
reduction in advanced outcomes) in 10 years
Scenario 4 : Morbidity and mortality prevention (90% 
reduction in advanced outcomes) in 15 years
Cost analysis : For the base case and all four scenari-
os, the cumulative cost of untreated HCV was calculated 
using the methodology (3) and inputs (14-16) previously 
described.
Residual risk of HCC analysis : The model does not 
consider the residual risk of HCC development among 
HCV cirrhotic patients who achieve SVR, so a secondary 
analysis was performed to estimate this burden. An HCC 
incidence rate of 1.02% was applied to the cirrhotic 
 population with SVR, after accounting for background 
mortality (17). 
Table 1. — Impact on viremic cases, HCC and liver related deaths in 10 and 15 years, by scenario,
compared with the current SOC
2015 Estimate 2026 Estimate % reduction, compared 
with Current SOC 2026
2031 Estimate % reduction, 
compared with 
Current SOC 2031
Viremic Cases
Current SOC 67,200 53,000 – 46,300 –
Scenario 1 67,200 5,100 90% 1,500 95%
Scenario 2 67,200 23,700 55% 4,500 90%
Scenario 3 67,200 25,500 50% 19,700 55%
Scenario 4 67,200 34,300 35% 20,700 55%
HCC
Current SOC 290 330 – 315 –
Scenario 1 290 25 90% 10 95%
Scenario 2 290 125 60% 25 95%
Scenario 3 290 30 90% < 5 > 95%
Scenario 4 290 115 65% 15 95%
Liver-related deaths
Current SOC 415 480 – 480 –
Scenario 1 415 55 90% 5 > 95%
Scenario 2 415 185 60% 65 85%
Scenario 3 415 45 90% 5 > 95%
Scenario 4 415 175 65% 45 90%
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Scenario 3 : Morbidity and mortality prevention (90% 
reduction in advanced outcomes) in 10 years
In order to reduce advanced stage outcomes by nearly 
90% in 10 years, the number of patients treated with 
higher SVR therapies would have to increase from 900 in 
2015 to 5,000 in 2018, with a 10% increase in annual 
diagnosed patients (from 2,850 in 2015 to 3,620 in 2020). 
Beginning in 2017, treatment would be provided to ≥ F2 
patients. At this treatment level, the majority of ≥ F2 pa-
tients would be treated by 2024, at which point annual 
treatment could be reduced to ~3,000 ≥ F2 patients 
through 2026. This scenario would result in a 90% reduc-
tion in HCV-related HCC and liver-related deaths by 
2026, and total HCV infections would be reduced by 
Scenario 2 : Near-viral elimination (90% reduction in 
viremic cases) in 15 years
In order to achieve near-viral elimination in 15 years, 
the annual increase in treatment with higher SVR thera-
pies would be less aggressive, from 900 in 2015 to 4,300 
in 2018. As in the 10-year scenario, treatment restrictions 
would need to be modified over time, including treatment 
of ≥ F2 patients beginning in 2016 and all patients (≥ F0) 
beginning in 2020. This scenario would result in a 90% 
reduction in total HCV infections and an 85%-95% re-
duction in HCV-related HCC and liver-related deaths by 
2031 (Fig. 1). The cumulative cost savings, compared 
with the current SOC, would be € 770 M (45%), over 
15 years (Fig. 2b).
Table 2. — The 10 year and 15 year cumulative cost of untreated HCV by scenario, compared with the current SOC
10 year (2016-2026) 15 year (2016-2031)
Cost - Cumulative Cumulative Cost Cost Savings Percent Reduction Cumulative Cost Cost Savings Percent Reduction
Current SOC € 1,136 – – € 1,709 – –
Scenario 1 € 606 € 530 45% € 659 € 1,050 60%
Scenario 2 € 763 € 373 35% € 928 € 780 45%
Scenario 3 € 775 € 362 30% € 1,019 € 690 40%
Scenario 4 € 881 € 255 20% € 1,180 € 529 30%
Fig. 1. — Annual treated patients, viremic cases, HCC and liver related deaths, by scenario - Scenario 1) Near-viral elimination (90% 
reduction in viremic cases) in 10 years ; Scenario 2) Near-viral elimination (90% reduction in viremic cases) in 15 years ; Scenario 
3) Morbidity and mortality prevention (90% reduction in advanced outcomes) in 10 years ; Scenario 4) Morbidity and mortality pre-
vention (90% reduction in advanced outcomes) in 15 years.
06-starkel-.indd   230 11/06/15   13:20
Reducing HCV prevalence of advanced outcomes 231
Acta Gastro-Enterologica Belgica, Vol. LXXVIII, April-June 2015
and treated patients, and explored the impact of time 
 delays on HCV-related outcomes. The current analysis 
expands on previous efforts by examining the steps 
 necessary to achieve meaningful goals of reducing preva-
lence and/or advanced outcomes by 90% in 10 or 
15 years. 
In all scenarios considered here, the number of pa-
tients treated annually with higher SVR therapies would 
increase from the current SOC, and patients with ≥ F2 
fibrosis would access treatment. Scenarios to reduce vire-
mic prevalence would require the treatment of all patients 
(≥ F0) ; however, the year in which treatment would be-
come unrestricted (2017 vs. 2020) depends on the desired 
endpoint (2026 vs. 2031). In addition to reducing preva-
lence, both scenarios projected a substantial reduction in 
HCC and liver-related deaths. By comparison, the sce-
narios designed to reduce advanced outcomes would re-
quire a less intensive scale-up of treatment to achieve the 
desired result, although, the effect on prevalence would 
be less substantial (35%-55% reduction by 2026, and 
55% reduction by 2031). 
As previously discussed, there are limitations sur-
rounding the historical inputs used in the model (2-4). A 
primary concern is a lack of robust and nationally repre-
sentative epidemiological studies to form a solid histori-
cal basis. To address this concern, all inputs used in the 
model were carefully chosen and agreed upon by the 
 Belgian HCV working group, comprised of local experts 
in the field of HCV. Moving forward, the working group 
recommends expanding current data collection systems 
to improve the availability of quality epidemiological 
data. For example, e-health is a web-based system of 
INAMI/RIZIV (Belgian health care authorities) which is 
used to grant immediate access to treatment, upon re-
quest by a physician. In the case of HCV, it currently 
registers basic patient data (age, sex, genotype, and fibro-
sis stage) Expanding this system to collect a broader 
50%. The cumulative cost savings, compared with the 
current SOC, would be € 395 M (35%), over 10 years 
(Fig. 2a).
Scenario 4 : Morbidity and mortality prevention (90% 
reduction in advanced outcomes) in 15 years
In order to reduce advanced stage outcomes by 90% in 
15 years, the number of patients treated with higher SVR 
therapies would need to increase from 900 in 2015 to 
3,100 in 2018, with restriction to ≥ F2 patients beginning 
in 2017. This scenario would result in a 95% reduction in 
HCV-related HCC and a 90% reduction in liver-related 
deaths by 2031. In addition, total HCV infections would 
be reduced by 55% (Fig. 1). The cumulative cost savings, 
compared with the current SOC, would be € 530 M 
(30%), over 15 years (Fig. 2b).
Residual risk of HCC
Under the current SOC, there would be 7-15 HCC 
cases annually among HCV cirrhotic patients achieving 
SVR during 2016 to 2031 (average = 11). Under the sce-
narios, there would be 8-36 HCC cases annually among 
cirrhotic patients achieving SVR (average = 24), regard-
less of the outcome (prevalence or mortality) or endpoint 
of interest (2026 or 2031).
Discussion 
The HCV therapeutic landscape has advanced rapidly 
since 2014, with the release of higher SVR therapies and 
an observed concurrent increase in the number of pa-
tients treated in the first quarter of 2015. These advance-
ments have prompted conversations about strategies to 
reduce the number of HCV infections and HCV-related 
advanced outcomes. Previous modeling efforts focused 
on conservative increases in the number of diagnosed 
Fig. 2. — Estimated cumulative health care cost of current standard of care, with cost savings associated with disease control strategies 
for a) 10-year strategies, and b) 15-year strategies, excluding the cost of treatment.
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Author Commentary :
“All of the scenarios presented need to be accompanied by an 
active screening strategy, since it is estimated that approxi-
mately half of the HCV patients are aware of their disease. 
Moreover, prevention in the groups at high risk of transmission 
(MSM, drug users, prisoners) will be necessary in a scenario of 
viral elimination.” – Christophe Moreno
“The costs associated with treating an increasing number of 
HCV patients are expected to be high. However, from a health 
economic point of view, the positive societal impact in terms of 
health gains and potential cost savings related to minimizing 
the burden of advanced stage disease are considerable. Well-
organized primary care and an overall implementation of 
 e-health are, however, prerequisites for early detection and 
quality of care follow-up.” – Dominique Vandijck
“Although the costs of treating a substantially higher number 
of patients could be high in the short term, it should be taken 
into account that the long-term impact on cumulative cost 
 burden might significantly outweigh these former. Insurance 
companies and government should definitely be made aware of 
this phenomenon.” – Hans Van Vlierberghe and Wim Laleman
“…In addition, ethical issues need to be taken into consider-
ation when identifying which patients will or won’t be treated.” 
– Pierre Van Damme 
“Models depend on the quality of the data that have been used 
to feed them. There is a lack of recent and good quality epide-
miological data in Belgium. Therefore, it is mandatory that 
health care authorities and health care professionals work 
 together and prospectively collect reliable data to allow valida-
tion of the model in the nearer future. The Belgium e-health 
system may be a suitable tool to achieve this objective.” – Peter 
Stärkel
range of parameters could not only inform the progress 
of HCV disease reduction efforts, but could also provide 
a means to prospectively update and validate the model 
used for this analysis. In addition, the conduct of an ac-
curate HCV sero-epidemiological study should be con-
sidered to validate the current estimations.
It is also possible that we underestimate the overall 
effect of all scenarios as we don’t take into consideration 
the reduction on transmission by curing an increasing 
number of patients. 
The Belgian HCV working group recommends work-
ing toward the elimination of HCV infections in Belgium 
over a 15-year time period (Scenario 2). This scenario 
balances outcomes (90% reduction in viremic prevalence 
and in HCC and liver-related deaths) with realistic re-
quirements for implementation (gradual increase in treat-
ment and delayed incorporation of patients with no/mild 
fibrosis).
Several considerations will be necessary before imple-
menting any of the scenarios presented here. Well- 
organized primary care and an overall implementation of 
e-health will be prerequisites for early detection and 
quality of care follow-up. Active screening strategies 
will also be necessary, as it is estimated that only half of 
HCV patients are aware of their disease. Moreover, pre-
vention efforts in high risk of transmission-groups (e.g. 
MSM, IV drug users, prisoners) will be important in a 
scenario of viral elimination. And finally, ethical issues 
should always be considered when identifying which 
 patients will be excluded from treatment.
In conclusion, this analysis demonstrates that it is 
 possible for Belgium to achieve this reduction by 2031, 
assuming a commitment is made to significantly increase 
treatment and diagnosis, utilize higher SVR therapies 
and expand eligibility to patients without fibrosis. Al-
though the costs of treating a substantially increased 
number of patients will be high in the short term, it should 
be taken into account that the long-term impact on cumu-
lative cost burden might be significantly improved.
References
1. VANDIJCK D., STARKEl P. Perspective editorial : Innovative strategies 
for hepatitis C in Belgium integrating treatment efficacy, public disease 
burden, and healtcare costs. Acta Gastroenterol. Belg., 2014, 77 : 274-276.
2. VAN DAMME P., lAlEMAN w., STARKEl P. et al. Hepatitis C 
Epidemiology in Belgium. Acta Gastroenterol. Belg., 2014, 77 : 277-279.
3. VANDIJCK D., MORENO C., STARKEl P. et al. Current and future health 
and economic impact of hepatitis C in Belgium. Acta Gastroenterol. Belg., 
2014, 77 : 285-290.
4. STARKEl P., VANDIJCK D., lAlEMAN w. et al. The Disease Burden of 
Hepatitis C in Belgium : development of a realistic disease control strategy. 
Acta Gastroenterol. Belg., 2014, 77 : 280-284.
5. BRuGGMANN P., BERG T., OVREHuS A.l. et al. Historical epidemiology 
of hepatitis C virus (HCV) in selected countries. J. Viral. Hepat., 2014, 21 
Suppl 1 : 5-33.
6. SARASwAT V., NORRIS S., ZuCKERMAN E. Historical epidemiology of 
hepatitis C virus (HCV) in select countries - volume 2. J. Viral. Hepat. 
Forthcoming, 2015.
7. wEDEMEyER H., DuBERG A.S., BuTI M. et al. Strategies to manage 
hepatitis C virus (HCV) disease burden. J. Viral. Hepat., 2014, 21 Suppl 1 : 
60-89.
06-starkel-.indd   232 11/06/15   13:20
